FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 227 filers reported holding FATE THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 0.97 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,051,342 | -55.5% | 495,916 | 0.0% | 0.21% | -79.5% |
| Q2 2023 | $2,360,560 | -16.5% | 495,916 | 0.0% | 1.02% | +34.0% |
| Q1 2023 | $2,826,721 | -73.0% | 495,916 | -52.2% | 0.76% | -71.5% |
| Q4 2022 | $10,465,913 | -55.0% | 1,037,256 | 0.0% | 2.67% | -51.5% |
| Q3 2022 | $23,245,000 | -9.6% | 1,037,256 | 0.0% | 5.51% | -5.2% |
| Q2 2022 | $25,703,000 | – | 1,037,256 | – | 5.81% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Polaris Venture Management Co. V, L.L.C. | 569,889 | $46,987,000 | 60.92% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,379,064 | $278,604,000 | 36.08% |
| Darwin Global Management, Ltd. | 1,370,133 | $112,967,000 | 22.12% |
| Redmile Group, LLC | 12,957,222 | $1,068,323,000 | 15.05% |
| Copernicus Capital Management, LLC | 8,000 | $660,000 | 10.66% |
| Casdin Capital, LLC | 3,400,000 | $280,330,000 | 8.35% |
| Grosvenor Holdings, L.L.C. | 1,123,576 | $92,639,000 | 6.81% |
| DAFNA Capital Management LLC | 314,360 | $25,919,000 | 6.15% |
| Ally Bridge Group (NY) LLC | 270,000 | $22,262,000 | 4.27% |
| Ghost Tree Capital, LLC | 185,000 | $15,253,000 | 3.58% |